The Missile Defense Agency awarded Long Wall $75 million to finish testing its Cyclops low-cost exo-atmospheric interceptor designed for midcourse interception. Long Wall, a rebranded ABL Space Systems focused on missile defense since February 2025, will invest an additional $75 million in private capital during the performance period.
What's happening
- MDA awarded $75 million to Long Wall to complete Cyclops testing, a liquid-fueled interceptor unveiled in December 2025.
- Long Wall will match the government award with $75 million in private investment for continued design and development work.
- Cyclops uses commercial off-the-shelf components and 3D printing, fitting inside shipping containers for ground or sea-based launch.
- The interceptor targets midcourse missile interception, complementing MDA's broader portfolio of low-cost air defense solutions.
Why it matters
- Low-cost interceptor production at scale reduces per-unit acquisition costs compared to traditional midcourse systems like Northrop Grumman's Ground-Based Interceptor.
- Containerized design and commercial-component architecture enable rapid deployment and distributed basing options for air defense networks.
- Private capital matching demonstrates investor confidence in startup-led missile defense development and reduces government funding pressure.
- MDA's parallel investment in X-Bow Systems and other low-cost alternatives indicates systematic portfolio approach to air defense modernization.
Going deeper
- Long Wall emerged from ABL Space Systems, a launch services company, signaling workforce and facility repurposing into missile defense production.
- Cyclops addresses the midcourse engagement phase; MDA also funds terminal-phase interceptors like X-Bow Systems' solid-fuel option as alternative to Patriot.
- Shipping-container basing enables dispersed air defense postures and reduces fixed-site vulnerability to first-strike attack.
Financial impact
- MDA obligates $75 million to Long Wall in the performance period; contract ceiling value and period of performance were not disclosed.
- Long Wall's $75 million private investment increases cash available for development and production tooling, extending runway and reducing future equity dilution.
- Revenue recognition depends on contract structure and milestones; testing completion and potential production orders would drive forward revenue into fiscal 2027 or later.
- Long Wall's balance sheet strengthens with matched funding, positioning the company for full-rate production contracts if Cyclops testing succeeds.
The intrigue
- Contract period of performance not disclosed by MDA or Long Wall, creating uncertainty around testing completion timeline and production readiness.
- Cyclops design freeze and manufacturing roadmap unclear; transition from testing to full-rate production and unit cost targets remain undisclosed.
The fine print
- Award is contingent on Cyclops meeting MDA performance and safety requirements; test results may alter production plans or program scope.
- Contract includes only $75 million obligated value; any production order would require separate procurement action and funding authorization.
Source: Breaking Defense · Oct 22, 2026 · Drafted with Claude, reviewed by Industrial Base Alpha.
